MAXIMUS (NYSE:MMS) has been awarded a one-year contract by the Centers for Medicare & Medicaid Services (CMS) to continue serving as an independent review entity for reconsiderations of beneficiary appeals for the Medicare Part D program.
The firm has performed this task since the Medicare prescription drug program was implemented in January 2006. The one-year contract is valued at approximately $14.3 million and includes a nine-month option period, which brings the total contract value to $25.0 million if this option is exercised.
“MAXIMUS is committed to providing unrivaled service in the administration of government health and human services programs as we seek to expand our client relationships, ” said MAXIMUS CEO Richard Montoni. “MAXIMUS Federal has been the sole provider of Part D appeal reconsiderations since the inception of the Medicare Part D program. This latest contract award from CMS underscores our role as a leading QIC and allows us the opportunity to process Medicare Part D reconsiderations across the entire country.”
